Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.

Fiche publication

Date publication

décembre 2023

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian , Dr JUNG Alain , Dr MARTIN Sophie , Dr BURGY Mickaël

Tous les auteurs :
Hélène C, Conrad O, Pflumio C, Borel C, Voegelin M, Bernard A, Schultz P, Onea MA, Jung A, Martin S, Burgy M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38066522

Résumé

Immune checkpoint inhibitors of programmed cell death protein 1 (PD-1) represent a significant breakthrough in treating head and neck squamous cell carcinoma (HNSCC), with long-lasting responses and prolonged survival observed in first- and second-line therapy. However, this is observed in < 20% of patients and high primary/secondary resistance may occur. The primary objective of the identification of predictive factors for the response to anti-PD-1 immunotherapy in head and neck squamous cell carcinoma (IPRICE) study is to identify predictive factors of response to anti-PD-1 immunotherapy.